Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have demonstrated anti-tumor activity in several advanced solid malignancies. In previously treated metastatic castration resistant prostate cancer (mCRPC), a small subset of patients have a therapeutic response to checkpoint inhibition. Those wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Harry J., Li, Yun Rose, Roach, Mack, Aggarwal, Rahul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450451/
https://www.ncbi.nlm.nih.gov/pubmed/32922519
http://dx.doi.org/10.1177/1758835920936084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450451/
https://www.ncbi.nlm.nih.gov/pubmed/32922519
http://dx.doi.org/10.1177/1758835920936084

Ejemplares similares